Several clinical trials have demonstrated that some patients with chronic myeloid leukemia
in chronic phase (CML‐CP) who achieve sustained deep molecular responses on tyrosine …

With BCR-ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, dasatinib,
bosutinib, and ponatinib, many patients with chronic myeloid leukemia in chronic phase …

BCR-ABL1 tyrosine kinase inhibitors have dramatically improved outcomes for patients with
chronic myeloid leukemia, and current studies are investigating whether some patients may …

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase
Inhibitors in Chronic Myeloid Leukemia Pat Page 1 NORMAS ORIENT AÇÃO Revista …

Zavedení inhibitorů tyrozinkináz dramaticky zlepšilo prognózu pacientů s chronickou
myeloidní leukemií. Očekávaná délka života pacientů při nově diagnostikovaném …

Introduction: Tyrosine kinase inhibitor (TKI) therapy has dramatically improved survival for
patients with chronic myeloid leukemia (CML). The focus of CML therapy is now shifting to …